Phase 2, Efficacy, Safety, and Pharmacokinetics Study of Two INV-202 Doses in Patients With Diabetic Kidney Disease
Study Details
Study Description
Brief Summary
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a Phase 2, randomized, double-blind, placebo controlled, dose ranging, multicenter study designed to assess the efficacy, safety, tolerability, and pharmacokinetics of INV-202 for the treatment of adult participants with a diagnosis of DKD due to either Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM) (diagnosed ≥1 year) who are on a stable anti diabetic medication regimen for ≥4 months prior with a HbA1c <9.5%. Approximately 240 participants (80/arm) will be randomized to 1 of 3 treatment arms in a 1:1:1 ratio: INV 202 10 mg, INV-202 25 mg, or placebo. The assigned study treatment will be taken once daily (QD), for 16 weeks.
Due to the high expected screen failure rates, participants may be pre-screened at sites with an approved pre-screening ICF.
Each participant will be allowed 1 retest during the screening period if they fail screening and 1 re-screening on a case by case basis with approval from the Worldwide medical monitors.
Study participation will last approximately 22 weeks and includes a Screening Period (up to 4 weeks), a Study Treatment Period with 16 weeks of daily study treatment, and a Safety Follow-Up Visit consisting of a phone call 2 weeks after the End of Treatment Visit (Week [W]18) to allow reporting of any adverse events following withdrawal of the study drug.
Any participant who withdraws before completing treatment will be requested to return for an Early Termination Visit, at which time the procedures normally scheduled for the W16 visit will be conducted.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: INV 202 10 mg INV-202 10 mg Arm |
Drug: INV-202
INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
Other Names:
|
| Experimental: INV-202 25 mg INV-202 25 mg Arm |
Drug: INV-202
INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
Other Names:
|
| Placebo Comparator: Placebo Placebo Arm |
Drug: Placebo
Placebo Matching size and number of tablets
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in UACR from baseline to W16 [16 weeks]
Measure of UACR at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)
Secondary Outcome Measures
- Change in urine protein to creatinine ratio (UPCR) from baseline to W16 [16 weeks]
Measure of UPCR at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)
- Change in eGFR using serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula from baseline to W16 [16 weeks]
Measure of eGFR using creatinine and CKD-EPI formula at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)
- Change in eGFR using cystatin C and the CKD-EPI formula from baseline to W16 [16 weeks]
Measure of eGFR using cystatin C and CKD-EPI formula at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female participants ≥18 years of age.
-
Able and willing to give informed consent and to comply with scheduled visits and trial procedures.
-
A diagnosis of DKD due to either T1DM or T2DM (diagnosed for ≥1 year)
-
On a stable anti-diabetic medication regimen for ≥4 months prior to randomization with a hemoglobin A1C (HbA1c) <9.5%.
-
Participants with T1DM may not be on any glucose lowering medications beyond insulin.
-
Participants with T2DM may be on more than 1 anti diabetic medication regimen (eg, SGLT2 inhibitor, insulin, or other anti-diabetic medication regimen).
-
HbA1c should have been performed within the last 4 months prior to randomization.
-
Participants must be on a stable dose of ACEi or ARB for ≥4 months prior to randomization and expected to remain stable for the 4-month treatment period.
-
Participants taking finerenone (not required), on a stable dose for ≥4 months prior to randomization.
-
Presence of albuminuria with a UACR >100 mg/g and <3000 mg/g at screening.
Exclusion Criteria:
-
Significant medical condition, that in the opinion of the Investigator will place the participant at risk during the study or that will confound the study endpoints.
-
Participants not fully vaccinated for Coronavirus Disease 2019 (COVID 19).
-
Participants will be considered fully vaccinated if they have received all recommended doses of a COVID-19 vaccine that has been authorized or approved by the United States Food and Drug Administration (FDA) or is listed for emergency use by the World Health Organization within 14 days prior to the first dose of the study drug.
-
Participants who have fully recovered from COVID 19 and have a negative COVID-19 test ≥14 days before screening are eligible.
-
Other causes of kidney disease that are not DKD (eg, lupus nephritis). Of note, hypertension is not an exclusion criteria.
-
Participants with an eGFR <30 ml/min/1.73m².
-
Participants who have had acute kidney injury (AKI) within the past 3 months, or have ever received dialysis.
-
Participants with a history of epilepsy or intracranial surgery.
-
Uncontrolled hypertension with measurements of systolic pressures >160 or diastolic measurements >100 at the Screening Visit.
-
Active substance abuse including inhaled or injection drugs in the year prior to screening.
-
Use of cannabis or cannabinoid containing compounds within 90 days prior to screening.
-
Pregnancy, planned pregnancy, potential for pregnancy or unwillingness to use effective birth control during the trial, as well as breast feeding.
-
Evidence of moderate to severe hepatic impairment as defined by Child's-Pugh B or C.
-
Subjects with a history of significant psychiatric disorder, including but not limited to:
-
Major depression within the last 2 years.
-
Any history of a suicide attempt or suicidal ideation.
-
Subjects with a history of other severe psychiatric disorders (eg, schizophrenia, bipolar disorder).
-
Score of the 9-question Patient Health Questionnaire (PHQ-9) ≥15 at baseline.
-
Current or active malignancy within the past 5 years, except for cancer in situ, or non-melanoma skin cancer such as basal cell or squamous cell carcinoma that has been completely resected.
-
QTc >500 msec at baseline.
-
Any chronic medications started or changed within the past 3 months or at risk of needing to be changed during the study.
-
Participants with a history of hyperthyroidism or other thyroid diseases.
-
Participants taking a strong inducer or inhibitor of cytochrome P450 3A4, 2D6 or 2C19 by screening. These medications are prohibited during the entire study duration.
-
Having taken any investigational compound within 30 days, or 5 half-lives of the drug, whichever is longer, before the Screening Visit.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Inversago Pharma Inc.
- Worldwide Clinical Trials
Investigators
- Study Director: Glenn Crater, MD, Inversago Pharma
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- INV-CL-106